Business
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
REDWOOD CITY, Calif., May 27, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.
About this update from Corcept Therapeutics Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":207,"url":"https://media.zenfs.com/en/business-wire.com/1227aa4a80fa37eee34990fe6bd038ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sxkMiBZlRq2iEzjFPXgqwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxNA--/https://media.zenfs.com/en/business-wire.com/1227aa4a80fa37eee34990fe6bd038ce","width":480,"height":207},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NQbhNHIc7pBbirovisPKMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI3Ng--/https://media.zenfs.com/en/business-wire.com/1227aa4a80fa37eee34990fe6bd038ce","width":480,"height":207}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., May 27, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.","length":495,"tagName":"p"},{"type":"text","content":""Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data," said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. "Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA in the coming weeks. The agency has told us to expect a Prescription Drug User Fee Act (PDUFA) date six months after the date of our submission. We appreciate the FDA’s continued engagement with our efforts to bring relacorilant’s benefits to patients with hypercortisolism."","length":602,"tagName":"p"},{"type":"text","content":"About Hypercortisolism (Cushing’s Syndrome)","length":43,"tagName":"p"},{"type":"text","content":"Hypercortisolism, also known as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, a...